Genentech Inc. and Galena Biopharma will work together in a mid-stage trial of Galena’s breast cancer therapy NeuVax in combination with South San Francisco-based Genentech’s Herceptin.
Financial terms of the deal, which includes The Henry M. Jackson Foundation for the Advancement of Military Medicine, were not disclosed.
No comments:
Post a Comment